Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences, a biopharmaceutical company, has reported a net income of $586.58 million for the quarter ended March 31, 2009, compared to $486.42 million for the quarter ended March 31, 2008.
Subscribe to our email newsletter
Net income attributable to Gilead was $589.11 million or $0.63 diluted earnings per share, for the first quarter of 2009, compared to $488.30 million, or $0.51 diluted earnings per share, for the same period of 2008.
For the first quarter of 2009, total revenues were $1.53 billion, a 22% increase, compared to $1.26 billion for the first quarter of 2008.
For the first quarter of 2009, total product sales were $1.45 billion, an increase of 27%, compared to $1.14 billion in the same quarter of 2008.